Daniel Ruiz-Sánchez

Daniel Ruiz-Sánchez

Auto-generated profile, based on publicly available information

Daniel Ruiz-Sánchez

Department of Dermatology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JVJara Valtueña
Jara Valtueña
DRDaniel Ruiz‐Sánchez
Daniel Ruiz‐Sánchez
VVVictor Volo
Victor Volo
PMPilar Manchado‐López
Pilar Manchado‐López
MGMaría Garayar‐Cantero
María Garayar‐Cantero

8 April 2019 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
MCMaría Garayar Cantero
María Garayar Cantero
MMMarina Canseco Martín
Marina Canseco Martín
ÁGÁngel Aguado García
Ángel Aguado García
DRDaniel Ruiz‐Sánchez
Daniel Ruiz‐Sánchez
JVJara Valtueña
Jara Valtueña
PLPilar Manchado López
Pilar Manchado López

14 August 2012 in Oncology Letters
Verified
Journal Article
Open access
PDF file
DRDaniel Ruiz-Sánchez
Daniel Ruiz-Sánchez
MCMiguel Alaguero Calero
Miguel Alaguero Calero
ASAlejandro José Sastre-Heres
Alejandro José Sastre-Heres
MIMaría-Teresa Iglesias-García
María-Teresa Iglesias-García
MHMiguel Angel Calleja Hernandez
Miguel Angel Calleja Hernandez
JPJaime Peña-Díaz
Jaime Peña-Díaz
A retrospective cohort study was conducted to analyse the effectiveness of bevacizumab and irinotecan (BVZ/CPT-11) as a second-line treatment in patients with primary glioblastoma multiforme (GBM) in comparison with a control group that were not administered BVZ/CPT-11 at the first recurrence. The difference in overall survival (OS) between the two groups was used as a predictor of effectiveness. OS was calculated according to prognostic factors and gender. A total of 28 and 32 patients were enrolled in the BVZ/CPT-11 cohort and control group, respectively. The median OS was 17.94 months (95% CI, 14.91–20.96) in the BVZ/CPT-11 treatment cohort and 10.97 months (95% CI, 7.65–14.30) in the control cohort. The results obtained on the effectiveness of BVZ/CPT-11 treatment in patients with primary GBM are consistent with data from previous studies. No significant differences were identified in OS based on prognostic factors; therefore, the latter cannot be used to select patients who would incur the greatest benefits from BVZ/CPT-11 treatment.

16 August 2020 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
ARAra H. Rostomian
Ara H. Rostomian
MTMaxine C. Tang
Maxine C. Tang
JSJonathan Soverow
Jonathan Soverow
DSDaniel R. Sanchez
Daniel R. Sanchez
The Systolic Blood Pressure Intervention Trial (SPRINT), a large randomized controlled trial funded by the National Institutes of Health, randomized 9361 patients with hypertension over 50 years of age and at least one cardiovascular risk factor to intensive (SBP < 120 mm Hg) or standard (SBP < 140 mm Hg) blood pressure treatment. The trial found a significant reduction in primary cardiovascular and mortality outcomes in the intensive treatment group. We performed an IRB‐approved post hoc analysis of the SPRINT trial data, recently made available through the NEJM SPRINT Data Analysis Challenge. Our subgroup analysis stratified subjects by age (≥75 years vs. <75 years) and presence or absence of pre‐existing chronic kidney disease (CKD) or cardiovascular disease (CVD). We found that intensive blood pressure control was associated with a significantly lower rate of the primary CVD outcome and all‐cause mortality in subjects age <75 years with no prior CVD or CKD and in subjects age ≥75 years with pre‐existing CVD or CKD.

12 November 2020 in International Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JVJara Valtueña
Jara Valtueña
GMGerardo Martínez‐García
Gerardo Martínez‐García
DRDaniel Ruiz‐Sánchez
Daniel Ruiz‐Sánchez
MGMaría Garayar‐Cantero
María Garayar‐Cantero
CDCarlos Dueñas
Carlos Dueñas
PMPilar Manchado‐López
Pilar Manchado‐López
Background: Coronavirus disease 2019 (COVID‐19) is a systemic multi‐organ viral illness. Previous studies have found that many patients had a procoagulant state and/or severe hypoxemia with relatively well‐preserved lung mechanics. Mechanisms underlying the damage to vascular tissues are not well‐elucidated yet. Histological data in COVID‐19 patients are still limited and are mainly focused on post‐mortem analysis. Given that the skin is affected by COVID‐19 and the relative ease of its histological examination, we aimed to examine the histology of skin lesions in COVID‐19 patients to better understand the disease’s pathology.Methods: Five skin lesions from COVID‐19 adult patients were selected for a deep histological tissue examination.Results: A strong vasculopathic reaction pattern based on prominent vascular endothelial and myointimal cell growth was identified. Endothelial cell distortion generated vascular lumen obliteration and striking erythrocyte and serum extravasation. Significant deposition of C4d and C3 throughout the vascular cell wall was also identified. A regenerative epidermal hyperplasia with tissue structure preservation was also observed.Conclusions: COVID‐19 could comprise an obliterative microangiopathy consisting on endothelial and myointimal growth with complement activation. This mechanism, together with the increased vascular permeability identified, could contribute to obliteration of the vascular lumen and hemorrhage in COVID‐19. Thus, anticoagulation by itself could not completely reverse vascular lumen obliteration, with consequent increased risk of hemorrhage. Findings of this study could contribute to a better understanding of physiopathological mechanisms underlying COVID‐19 on living patients and could help further studies find potential targets for specific therapeutic interventions in severe cases.

15 July 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
DRDaniel Ruiz-Sánchez
Daniel Ruiz-Sánchez
IPIrene Iglesias Peinado
Irene Iglesias Peinado
MAMiguel Alaguero-Calero
Miguel Alaguero-Calero
ASAlejandro José Sastre-Heres
Alejandro José Sastre-Heres
BDBenito García Diez
Benito García Diez
JPJaime Peña-Díaz
Jaime Peña-Díaz
The purpose of the present study was to calculate the cost-effectiveness of the inclusion of the bevacizumab (BVZ) + irinotecan (CPT-11) regimen in the second-line of treatment for primary glioblastoma multiforme. A retrospective cohort study with a control group was performed in which the cost-effectiveness of a course of chemotherapy was calculated based on survival time and the incremental cost between the two lines of treatment. A total of 77 patients were included, 36 of who formed the BVZ/CPT-11 cohort. The median survival time for the non-BVZ control cohort was 13.23 months [95% confidence interval (CI), 11.79–14.68], while for the BVZ/CPT-11 treatment cohort, the median survival time was 17.63 months (95% CI, 15.38–19.89). Overall, each year of life gained for each patient treated with BVZ/CPT-11 would cost €46,401.99. These results demonstrate the effectiveness of the BVZ/CPT-11 combination, but its incremental cost compared with other lines of treatment or the best care available does not appear to be acceptable for public health systems in the current situation of budgetary adjustments.